NysnoBio
Mill Valley
About NysnoBio
NysnoBio was the first to discover the Parkin gene, which has been related to Parkinson's disease. They were the first to show Parkin is an E3 ubiquitin ligase, the first to publish a crystal structure proving essential parts of enzymology, the first to use AAV in gene therapy, and in clinical neuroimaging, ensuring decisive outcomes in the clinic.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $2.5M
- Last round: Grant (Jan 2025)
- Website: nysnobio.com
Industries & Categories
Health Care
Social Profiles
Canonical: https://fsome.com/organization/nysnobio-131120 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.